Therapy News and Research

RSS

Regado receives Fast Track designation from FDA for REG1

Regado Biosciences, Inc., a biopharmaceutical company focused on the development of actively controllable therapeutics, today announced that the United States Food and Drug Administration has designated REG1 for anticoagulant therapy to be used in patients with coronary artery disease during percutaneous coronary interventions (PCI) as a Fast Track development program.

10 Mar 2014

FDA accepts Lundbeck's carbamazepine NDA for review

Lundbeck LLC today announced that the U.S. Food and Drug Administration has accepted for review a New Drug Application (NDA) for its investigational therapy intravenous carbamazepine, an intravenous formulation of the anti-epileptic drug (AED) carbamazepine. An action letter is anticipated before the end of 2014. Carbella is the proposed U.S. trade name for intravenous carbamazepine.

10 Mar 2014

Antares Pharma announces launch of OTREXUP to Dermatologists

Antares Pharma, Inc. today announced LEO Pharma's launch of OTREXUP to Dermatologists, the first U.S. Food and Drug Administration approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.

10 Mar 2014

New research reveals how substance abuse problems take hold in returning veterans

Of nearly 1 million veterans who receive opioids to treat painful conditions, more than half continue to consume opioids chronically or beyond 90 days, new research says. Results presented at the 30th Annual Meeting of the American Academy of Pain Medicine reported on a number of factors associated with opioid discontinuation with the goal of understanding how abuse problems take hold in returning veterans.

10 Mar 2014

Mainstay Medical initiates clinical trial to investigate ReActiv8 as treatment for adults with CLBP

Mainstay Medical today announced that it has secured approval from Ethics Committees in Australia to start a clinical trial of ReActiv8, its innovative implantable neurostimulation device for the treatment of people with Chronic Low Back Pain (CLBP). Recruitment of subjects for the trial has commenced at three clinical sites in Australia.

10 Mar 2014

Study: Stem cell transplant effective in halting degenerative disc disease of spine

Stem cell transplant was viable and effective in halting or reversing degenerative disc disease of the spine, a meta-analysis of animal studies showed, in a development expected to open up research in humans.

10 Mar 2014

Tucson offers unique form of hormone replacement therapy, SottoPelle

Dr. Frank Comstock, whose office is located at 6127 N. La Cholla, Suite 175, in Tucson, is now offering SottoPelle®, a unique form of hormone replacement therapy, developed by internationally recognized Gino Tutera M.D., F.A.C.O.G., as a solution for patients who struggle with hormone imbalance and well-being.

10 Mar 2014

Proteus Digital Health teams up with leading organisations to bring digital health technology to the UK

Leading digital medicines company Proteus Digital Health is partnering with Eastern Academic Health Science Network, The Northern Health Science Alliance and Oxford University, Oxford University Hospitals NHS Trust and Oxford Academic Health Science Network to bring digital health technology and global operations and manufacturing to the UK.

10 Mar 2014

Scientists use novel metagenomic approaches to characterize microbial communities that reside in human gut

The gut microbiota contains a vast number of microorganisms from all three domains of life, including bacteria, archaea and fungi, as well as viruses. These interact in a complex way to contribute towards both health and the development of disease - interactions that are only now being elucidated thanks to the application of advanced DNA sequencing technology in this field.

10 Mar 2014

Takeda works with UCL to drive research into tackling muscle disorders

Japanese pharmaceutical company Takeda will work with University College London (UCL) to drive research into tackling muscle disorders, in particular muscular dystrophy.

10 Mar 2014

Erlotinib has promising potential to improve treatment for cervical cancer

A new clinical study has found that erlotinib, a targeted antitumor agent, has promising potential to improve treatment for cervical cancer. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the results indicate that larger trials are warranted to determine whether the drug should become part of standard therapy for women with the disease.

10 Mar 2014

Dr. Daniel D. Von Hoff named one of ASCO's 50 Oncology Luminaries

In association with its 50th anniversary, the American Society of Clinical Oncology has named Dr. Daniel D. Von Hoff one of ASCO's 50 Oncology Luminaries, celebrating 50 doctors who over the past half-century have significantly advanced cancer care.

9 Mar 2014

Aptel Research releases newest report Patient Voices Series Rheumatoid Arthritis

Aptel Research, a specialty marketing research and consulting company that provides actionable strategic insights to the pharmaceutical and biotech industries, released its newest report Patient Voices Series Rheumatoid Arthritis (US).

8 Mar 2014

Longtime allies team up to create Penn Medicine/CHOP Friedreich's Ataxia Center of Excellence

Three longtime allies have joined forces to create the new Penn Medicine/CHOP Friedreich's Ataxia Center of Excellence.

7 Mar 2014

National clinical trial to test new avenue for tinnitus treatment

UT Southwestern Medical Center will take part in a national clinical trial to test a device that could provide relief for people suffering from tinnitus, a persistent buzzing or ringing sound in the ears. The device uses nervous system stimuli to rewire parts of the brain, in hopes of significantly reducing or removing tinnitus.

7 Mar 2014

Agendia co-founder to be honored with 2014 European Union Prize for Women Innovators

Agendia co-founder Laura van 't Veer, Ph.D., will receive a 2014 European Union Prize for Women Innovators in ceremonies next Monday. Dr. van 't Veer, of the Netherlands, is the inventor of Agendia's MammaPrint® breast cancer test.

7 Mar 2014

BWH researchers explore newer approaches to treat Alzheimer's disease

A team of Alzheimer's disease (AD) researchers at Brigham and Women's Hospital (BWH) has been able to study the underlying causes of AD and develop assays to test newer approaches to treatment by using stem cells derived from related family members with a genetic predisposition to (AD).

7 Mar 2014

Treating long wait-times dictate long-term success of spinal cord stimulation therapy

Success rates soared to 75% for patients who waited less than 2 years for a spinal cord stimulator (SCS) implant, compared with 15% for patients whose implants happened 20 years after the onset of pain, according to a retrospective analysis.

7 Mar 2014

Incyte Corporation publishes results of Phase III trial of ruxolitinib in patients with polycythemia vera

Incyte Corporation (Nasdaq: INCY) today announced that a pivotal Phase III trial of ruxolitinib compared to best available therapy in patients with polycythemia vera who are resistant to or intolerant of hydroxyurea has met its primary endpoint of achieving phlebotomy independence and reducing spleen size by 35 percent or more.

7 Mar 2014

Vitamin D boosts survival of breast cancer patients

Breast cancer patients with high levels of vitamin D in their blood are twice as likely to survive the disease as women with low levels of this nutrient, report University of California, San Diego School of Medicine researchers in the March issue of Anticancer Research.

7 Mar 2014

Therapy News and Research

Regado receives Fast Track designation from FDA for REG1

FDA accepts Lundbeck's carbamazepine NDA for review

Antares Pharma announces launch of OTREXUP to Dermatologists

New research reveals how substance abuse problems take hold in returning veterans

Mainstay Medical initiates clinical trial to investigate ReActiv8 as treatment for adults with CLBP

Study: Stem cell transplant effective in halting degenerative disc disease of spine

Tucson offers unique form of hormone replacement therapy, SottoPelle

Proteus Digital Health teams up with leading organisations to bring digital health technology to the UK

Scientists use novel metagenomic approaches to characterize microbial communities that reside in human gut

Takeda works with UCL to drive research into tackling muscle disorders

Erlotinib has promising potential to improve treatment for cervical cancer

Dr. Daniel D. Von Hoff named one of ASCO's 50 Oncology Luminaries

Aptel Research releases newest report Patient Voices Series Rheumatoid Arthritis

Longtime allies team up to create Penn Medicine/CHOP Friedreich's Ataxia Center of Excellence

National clinical trial to test new avenue for tinnitus treatment

Agendia co-founder to be honored with 2014 European Union Prize for Women Innovators

BWH researchers explore newer approaches to treat Alzheimer's disease

Treating long wait-times dictate long-term success of spinal cord stimulation therapy

Incyte Corporation publishes results of Phase III trial of ruxolitinib in patients with polycythemia vera

Vitamin D boosts survival of breast cancer patients

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News